Biochemical safety and efficacy of co-administration of Ezetimibe and simvastatin among patients with chronic kidney disease: The second UK-Heart and renal protection (UK-HARP-II) study
Päätekijät: | Landray, M, Baigent, C, Leaper, C |
---|---|
Aineistotyyppi: | Conference item |
Julkaistu: |
2003
|
Samankaltaisia teoksia
-
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.
Tekijä: Landray, M, et al.
Julkaistu: (2006) -
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Tekijä: Baigent, C, et al.
Julkaistu: (2005) -
Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: Final results of the first UK-Heart and Renal Protection (UK-HARP-1) study.
Tekijä: Baigent, C, et al.
Julkaistu: (2002) -
Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
Tekijä: Alexander, W, et al.
Julkaistu: (2011) -
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Tekijä: Baigent, C, et al.
Julkaistu: (2011)